

Form 51-102F3
Material Change Report

PART 1 GENERAL INSTRUCTIONS AND INTERPRETATION

(a) Confidentiality

If this Report is filed on a confidential basis, state in block capitals "CONFIDENTIAL" at the beginning of the Report.

(b) Use of "Company"

Wherever this Form uses the word "company" the term includes other types of business organizations such as partnerships, trusts and other unincorporated business entities.

(c) Numbering and Headings

The numbering, headings and ordering of the items included in this Form are guidelines only. You do not need to include the headings or numbering or follow the order of items in this Form. Disclosure provided in response to any item need not be repeated elsewhere.

(d) Defined Terms

If a term is used but not defined in this Form, refer to Part 1 of National Instrument 51-102 and to National Instrument 14-101 *Definitions*. If a term is used in this Form and is defined in both the securities statute of a local jurisdiction and in National Instrument 51-102, refer to section 1.4 of Companion Policy 51-102CP.

(e) Plain Language

Write the Report so that readers are able to understand it. Consider both the level of detail provided and the language used in the document. Refer to the plain language principles listed in section 1.5 of Companion Policy 51-102CP. If you use technical terms, explain them in a clear and concise manner.

PART 2 CONTENT OF MATERIAL CHANGE REPORT

Item 1 Name and Address of Company

Nanton Nickel Corp.
Suite 800 - 1199 West Hastings Street
Vancouver, British Columbia, V6E 3T5

Item 2 Date of Material Change

October 4, 2013

Item 3 News Release

A news release was disseminated on October 4, 2013 through the facilities of Stockwatch.

Item 4 Summary of Material Change

Nanton announces the cancellation of the Memorandum of Understanding dated July 12, 2013 for the acquisition of all assets and intellectual property related to US Patent No. 13/549,862 from Caduceus Medical LLC.

Item 5 Full Description of Material Change

The Memorandum of Understanding dated July 12, 2013 for the acquisition of all assets and intellectual property related to US Patent No. 13/549,862 from Caduceus Medical LLC was cancelled.

The Company continues to work towards the acquisition of a technology asset, with the goal of completing a change of its business to a technology issuer a high priority.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) or (3) of National Instrument 51-102.

Item 7 Omitted Information

No information has been omitted on the basis that it is confidential information.

Item 8 Executive Officer

Adam Cegielski is knowledgeable about the material change and the Report and may be contacted (604) 304.0068.

Item 9 Date of Report

October 4, 2013